Xenter is launching new wireless technologies for interventional medicine, creating a digital health platform that will aggregate devices, medical data and diagnostics to enable better patient outcomes
Revolutionizing Data Collection in Cardiology with Proprietary Wireless Ecosystem November 08, 2023 09:00 AM Eastern Standard Time DRAPER, Utah–(BUSINESS WIRE)–Xenter, Inc. (Xenter.io) announced the recent
11:30am on Thursday, Nov. 17, 2022: Utah Valley University Presidential Lecture Series will feature Keynote Speaker Elazer R. Edelman, M.D., Ph.D. (world renowned cardiologist, biomedical
DRAPER, Utah — November 02, 2022 —Florida-based Palm Vascular Centers is the first healthcare organization to deploy XenFI™, the recently announced wireless medical ecosystem from
DRAPER, Utah — October 05, 2022 — In an effort to improve the adoption of new technology in healthcare, Xenter™ today unveiled XenFI™, the first
October 18, 2021 09:00 AM Eastern Daylight Time SALT LAKE CITY—Xenter this week announced that it has appointed Tony Collins as chief financial officer. Collins most
UTAH
Xenter Inc. Headquarters
344 West 13800 South Suite 400
Draper, UT 84020
385.799.6400
[email protected]
CALIFORNIA
Xenter Inc.
1817 Aston Avenue, Suite 105
Carlsbad, CA 92008
© 2023 Xenter, Inc.
344 West 13800 South
Suite 400
Draper, UT 84020
Mr. Linder has served as a member of the Board of Directors for the Boy Scouts of America (Salt Lake City, UT) and was the Executive Vice President of Finance. He has served on the Board of Directors for many private and public companies including Rubicon Medical, Coherex Medical, CoNextions Medical, Juneau BioScience, Vital Access Corp., and Dynatronics. He has been an invited speaker, meeting faculty, panelist, and Keynote speaker at Transcatheter Cardiovascular Therapeutics (TCT), American College of Cardiology (ACC), Dartmouth 3D, BioUtah Life Science Summit, and many other conferences and meetings. Mr. Linder attended both Brigham Young University and the University of Utah where he studied Business Management and Organizational Behavior. Mr. Linder is the inventor of many medical devices in Interventional Cardiology, Interventional Radiology, Neuro-Interventional Radiology, Orthopedic Surgery, Female Reproductive Medicine, and a Percutaneous Left Ventricular Assist Device (LVAD). He is an inventor on over 100 US and international patents for medical device technologies. Mr. Linder has been in many countries around the world and has overseen several multi-center clinical research trials for medical devices. Mr. Linder is the recipient of the Utah Governor’s Medal for Science & Technology.
James R. Tobin has been at the helm of 5 different companies. Mr. Tobin is Chairman for TransMedics Group, Inc. and Chairman at TransMedics, Inc. (a subsidiary of TransMedics Group, Inc.). He has been on the board of over 20 companies, currently serving on the boards of Globus Medical, Oxford Immunotec and TransMedics.
Mr.Tobin served as President and Chief Executive Officer of Boston Scientific from March 1999 to July 2009. Before joining Boston Scientific, Mr. Tobin served as the President and CEO of Biogen, Inc., from 1997 to 1998 and as its Chief Operating Officer from 1994 to 1997. Mr. Tobin also worked at Baxter International in various capacities from 1972 to 1994, including as its President and Chief Operating Officer from 1992 to 1994. Mr. Tobin also currently serves on the board of directors of Oxford Immunotech Global PLC (NYSE: OXFD), a global diagnostics company, Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics and two private companies, TransMedics, Inc., and Resolys Bio, Inc.
He served as a Lieutenant in the U.S. Navy from 1968 to 1972. Mr. Tobin holds an M.B.A. from Harvard Business School and an A.B. from Harvard College. He is well qualified to serve on our board of directors and on our Audit Committee and Nominating and Corporate Governance Committee for numerous reasons, including his decades of experience as a senior executive of large multinational healthcare and medical device companies, and his service as a director of Boston Scientific Corporation.
Robert S. Langer, ScD, is one of 12 Institute Professors at the Massachusetts Institute of Technology (MIT); being an Institute Professor is the highest honor that can be awarded to a faculty member. He has written more than 1,500 articles, which have been cited more than 340,000 times; his h-index of 286 is the highest of any engineer in history and tied for the 4th highest of any individual in any field. His patents have been licensed or sublicensed to more than 400 companies. He served as Chairman of the FDA’s Science Board (its highest advisory board) from 1999-2002. His over 220 awards include both the United States National Medal of Science and the United States National Medal of Technology and Innovation (he is one of 3 living individuals to have received both these honors), the Charles Stark Draper Prize (often called the Engineering Nobel Prize), Queen Elizabeth Prize for Engineering, Albany Medical Center Prize, Breakthrough Prize in Life Sciences, Kyoto Prize, Wolf Prize for Chemistry, Millennium Technology Prize, Priestley Medal (highest award of the American Chemical Society), Gairdner Prize, and the Dreyfus Prize in Chemical Sciences. He holds 35 honorary doctorates and has been elected to the National Academy of Medicine, the National Academy of Engineering, the National Academy of Sciences and the National Academy of Inventors.
Board Member/Founding Scientific Advisor/Chair of Scientific Advisory Board
Dr. Edelman received Bachelor of Science degrees in Bioelectrical Engineering and in Applied Biology from MIT, a Master of Science degree in Electrical Engineering and Computer Sciences from MIT, a Ph.D. in Medical Engineering and Medical Physics from MIT, and an M.D. degree from Harvard Medical School. His graduate thesis work, under the direction of Prof. Robert Langer, defined the mathematics of regulated and controlled drug delivery systems. After internal medicine training and clinical fellowship in Cardiovascular Medicine at the BWH he spent six years as a research fellow in the Department of Pathology at Harvard Medical School with Prof. Morris J. Karnovsky working on the biology of vascular repair. Many of his findings have been or are now in clinical trial validation. More than 300 students and postdoctoral fellows have passed through Dr. Edelman’s laboratory enabling publication of more than 680 original scientific articles and some 80 patents.
Dr. Edelman is a fellow of the American College of Cardiology, the American Heart Association, the Association of University Cardiologists, the American Society of Clinical Investigation, American Institute of Medical and Biological Engineering, the American Academy of Arts and Sciences, National Academy of Inventors, the National Academy of Medicine, and the National Academy of Engineering.
Mark Stautberg has more than 35 years of medical device Sales & Marketing experience, most notably at Boston Scientific as the Senior Vice President, Sales for the Cardiovascular businesses. As SVP from 1998-2004, he grew sales ten-fold & led the launch of the TAXUS Drug Eluting Stent to unprecedented adoption, market share, revenue & speed. During Mark’s entire fourteen plus years at Scimed/Boston Scientific, he held key roles that led to their position as the leading company in Interventional Cardiology. Prior to Boston Scientific, Mark had roles of increasing responsibility at Baxter International, including Director of Marketing for the Hospital Supply Division. He also served on numerous medical device company Boards, both private & public, where he mentored commercial teams to success. Mark has a BBA in Marketing from the University of Cincinnati.
Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.
Vice President of Finance
Bret Peterson is an experienced finance professional with over 20 years in the medical device business. He has held various leadership positions in the Neurovascular business for Boston Scientific and Stryker, as well as a Neurovascular startup (Precision Vascular Systems) that was sold to Boston Scientific in 2004. He is skilled in implementing internal controls, acquisition integrations, strategic and financial planning, accounting and standard cost development.
Mr. Peterson was responsible for integrating several acquisitions for Stryker and ensuring they were properly incorporated into Stryker’s financial systems. Mr. Peterson also helped formulate and implement several money saving initiatives relating to facility expansion and manufacturing consolidation that resulted in $15M+ annual savings.
Mr. Peterson graduated from Brigham Young University with a Master of Management Accounting degree and currently lives in Draper, UT with his family.
Raised in Southern California, Mr. Pearson graduated summa cum laude in 1992 from Brigham Young University with degrees in History and Portuguese and then in 1995 from Harvard Law School, where he served as an editor on the Harvard Law Review. Before joining the Xenter team, Mr. Pearson built a vibrant law practice in Salt Lake City focused on business relationships and corporate transactions, advising a wide range of clients that include software companies, restaurant owners, private equity firms, asset-based commercial lenders, airlines, Web-based retailers, oil and gas ventures, gold and copper mining companies, real estate syndicators, registered broker-dealers and real estate developers.
Mr. Pearson has a keen interest in the interplay between emerging technologies and the law. Eric’s tech hobbies include coding in Python. From 2003 to 2009, he and a partner built and sold eWatches.com, an ecommerce business specializing in wristwatches. Eric built a cryptocurrency mining rig from scratch. He most likely owns the high score for Galaga at DefCon 27’s arcade party.
Mr. Pearson has served as a founding board member of Team Kid Courage, a non-profit dedicated to helping children with disabilities, participate in sporting and other active events notwithstanding their physical limitations. Eric enjoys spending time with his wife, children and grandchildren, and is an avid skier, marathoner and mountaineer.
Vice President of Intellectual Property
Mr. Jensen graduated from the University of Utah with a degree in Mechanical Engineering and worked as an engineer for several years prior to attending law school and the University of Houston, where he graduated cum laude. Before joining Xenter, Mr. Jensen had a successful practice in intellectual property law representing a diverse clientele that ranged from individual inventors to some of the largest companies in the world.
Mr. Jensen has extensive experience in intellectual property law including patent preparation and prosecution, trademark prosecution, freedom to operate and infringement analysis, post grant procedures with the U.S. Patent and Trademark Office, trademark oppositions, and patent and trademark litigation.
Mr. Jensen’s patent practice has involved a variety of technologies including medical devices, aerospace technologies, oil and gas technologies, manufacturing processes and materials science, alternative energy, filtration and separation technologies, mining, input devices for consumer electronics, exercise equipment and sporting goods, firearms, and business methods and software.
Mr. Jensen has been honored to be included in Utah’s Legal Elite, Mountain States Super Lawyers, and The Best Lawyers in America® for multiple years.
Mr. Jensen enjoys spending time with his wife, children, and grandchildren. He also enjoys the outdoors, fly fishing, and photography.
Vice President of Information Technology
Ekstrom loves to serve, share, mentor, and learn from others. In addition to his extensive IT background, professional role at the U of U and now Xenter, Ekstrom has served on the board of Westnet (consortium of higher-ed IT leaders) and served as President.
Ekstrom has 30+ years of experience building, maintaining, and growing enterprise class services for IT, health care and academic organizations.
Ekstrom’s career started in his teens as he worked with his older brother on run-length encoding as a full-text indexing compression algorithm. He graduated cum laude from Brigham Young University. He was privileged to work with Dr. Helmuth Orthner, PhD and Dr. Homer Warner, MD, PhD researching and deploying clinical solutions across the University Health organization as part of the University of Utah Medical Informatics program. Ekstrom gained a reputation as someone deeply committed to driving clinical solutions that were reliable and valuable—including the deployment and support of both the Cerner and EPIC electronic health records over the next 13 years. In 2013, Ekstrom was asked to bring his customer service and enterprise mindset to the broader IT vision in a campus-wide role. In that role, Ekstrom’s leadership role included everything from network and data center services to communications infrastructure technologies. These solutions served both the health care and broader academic mission. Cloud services like O365, Gmail, Box, Teams, etc. were also a part of his portfolio. Ekstrom enjoys playing a key role in bringing innovation across traditional boundaries and avoiding a silo mentality.
Founding Scientific Advisor/Senior Medical Director
Founding Scientific Advisor/Senior Medical Director
Barry T. Katzen, M.D., is the founder and chief medical executive Emeritus of Miami Cardiac & Vascular Institute, a Baptist Health South Florida center of excellence. He is professor and founding chairman of the Department of Interventional Radiology and professor of Surgery at the FIU Herbert Wertheim College of Medicine.
He has had a distinguished clinical career and is considered one of the pioneers of interventional radiology, nationally and internationally. In developing the Institute more than 30 years ago, Dr. Katzen established a long history of innovation within the organization, creating a unique culture of multidisciplinary collaboration to improve patient care, as well as developing numerous new procedures and devices pioneered at Miami Cardiac & Vascular Institute.
Dr. Katzen has participated in and gained experience in the process of innovation throughout his career. From bringing innovative changes to healthcare delivery, the development of transformational devices including vascular stents, endovascular grafts, unique devices for delivery of thrombolytic agents, and all forms of devices for minimally invasive therapies of vascular diseases.
His opinions about new technology are regularly sought by established companies and startups from around the world. Dr. Katzen has shown his ability to influence successful development by integrating his fundamental knowledge of medicine and unmet needs, with a strong predictive sense of what might work well in developing technological solutions for clinical challenges.
Dr. Katzen is a graduate of the University of Miami School of Medicine with a residency at New York Hospital-Cornell Medical Center. He studied in London and Rome three distinct times during his educational career. He has been recognized with gold medals and honorary memberships in national and international professional societies and was awarded the Leaders in Innovation Award by the Society of Interventional Radiology.
Dr. Katzen’s passion for innovation led to the formal initiation of an innovation program at Baptist Health in 2016, through supporting changes in the organization’s vision statement to include commitment to innovation as a program and process.
Founding Scientific Advisor
Scientific Advisor
Scientific Advisor
Dr. Evan Shlofmitz is an Interventional Cardiologist and the Director of Intravascular Imaging at St. Francis Hospital – The Heart Center in Roslyn, NY. He completed a fellowship in Interventional Cardiology at Georgetown University/MedStar Washington Hospital Center. He previously completed an Intravascular Imaging and Physiology fellowship at the Cardiovascular Research Foundation (CRF) and Columbia University Medical Center (CUMC), a Cardiovascular Disease fellowship at Northwell Health and served as Chief Resident for Internal Medicine at New York Presbyterian Queens. He serves on SCAI’s Ischemic Heart Disease Council and is a co-director of Optimizing PCI (OPCI). Dr. Shlofmitz has a strong interest in clinical education, lecturing internationally. His research interests have centered on intravascular imaging, the treatment of calcified coronary artery disease, in-stent restenosis and the optimization of stent implantation, with more than 130 publications in peer-reviewed journals.
Dr. Mintz completed his undergraduate education at the University of Pennsylvania in 1970 and received his medical degree from Hahnemann University in 1974, both in Philadelphia, PA. He finished his internship in 1975, residency in 1976, and cardiology fellowship in 1978, each at Hahnemann University. He joined the Hahnemann University Department of Medicine in 1978 and was promoted to Professor of Medicine in 1987 before joining CRF in 1991. His administrative appointments there included Director of the Cardiac Ultrasound Laboratory, Director of the Coronary Care Unit, and Director of the Cardiology Fellowship Training Program. He received teaching awards from both the Department of Medicine Residency and Cardiology Fellowship Training Programs.
Scientific Advisor
Gregg W. Stone is Professor of Medicine at the Columbia University Medical Center, Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital, and Co-Director of Medical Research and Education at the Cardiovascular Research Foundation in New York, NY. Dr. Stone has served as the national or international principal investigator for more than 80 national and international multicenter randomized trials, has authored more than 2000 book chapters, manuscripts and abstracts published in the peer-reviewed literature, and has delivered thousands of invited lectures around the world. Dr. Stone’s areas of expertise include interventional therapies of acute coronary syndromes and myocardial infarction; drug-eluting stents; antiplatelet and antithrombotic pharmacotherapies; transcatheter mitral valve repair and replacement; new device angioplasty including atherectomy, distal embolic protection, thrombectomy, vascular brachytherapy, and stent grafts; saphenous vein graft therapies; intravascular imaging; chronic total occlusions; left atrial appendage closure; vulnerable plaque; contrast nephropathy; clinical trial design; and regulatory issues. Dr. Stone, along with Dr. Martin B. Leon, is the director of Transcatheter Cardiovascular Therapeutics (TCT), the world’s largest symposium devoted to interventional cardiology and vascular medicine, directs the annual National Interventional Cardiology Fellow’s Course, and co-directs multiple other annual courses, including Optimizing Complex PCI Outcomes, The Left Main and Chronic Total Occlusion Summit, Bioresorbable Scaffolds: A Breakthrough PCI Technology, LAA Occlusion: A Technique Oriented Course, and Transcatheter Valve Therapies. Dr. Stone’s medical practice is devoted to interventional cardiology at New York-Presbyterian Hospital and Columbia University Medical Center.
Honors & Awards
Research Fellowship Award, Southern Pennsylvania Heart Assoc. 1978-1980
Member, PTCA Subcommittee NHLBI-Study of Thrombolysis in
Acute Myocardial Infarction (TIMI) 1986-1987
Consultant: FDA Committee on Biologics 1986
Chairman: New York Angioplasty Society 1987-1988
Lectureship, Sendai Medical College, Tohoku Medical Society,
Sendai, Japan 1990
Lectureship, The Vivian & Norman Weiden Lecture: Innovative
Approaches to Coronary Artery Disease 1996
New York Cardiological Society, NYC
Listed in Best Doctors of the Year, New York Magazine 2004-2016
America’s Top Doctors –Castle Connolly 2005-2016
Lifetime Achievement Award, Cardiovascular Research Foundation 2006
C3 Lifetime Career Achievement Award-C3 Hall of Fame 2010
Scientific Advisor
Douglas L. Packer, MD, is a Professor of Medicine, and the John M. Nasseff, Sr., Professor in Cardiovascular Diseases in the Department of Cardiovascular Diseases, Division of Cardiac Electrophysiology, at Mayo Clinic Rochester. He is Director of the Translational Electrophysiology Research Laboratory. Dr. Packer is internationally known in cardiac electrophysiology.
Dr. Packer attended Brigham Young University, where he received a Bachelor of Arts in chemistry, summa cum laude, in 1976. He then acquired a Doctor of Medicine from the University of Utah in 1980. Additional educational pursuits include an internship and residency in internal medicine at Duke University from 1980 to 1983, where he served as an assistant chief resident in internal medicine. He also trained there as a fellow of cardiology and electrophysiology from 1983 to 1985.
His honors and awards include the Haskel Schiff Award in Internal Medicine from Duke University in 1983, the Distinguished Service Award from Brigham Young University in 2006, and the Distinguished Scientist Award from the American College of Cardiology in 2019. Dr. Packer has also received the Eric Prystowsky Advocate for Patients Award from the Stopafib.org patient-centered organization in 2018, the Eric N. Prystowsky Lectureship Award from the National Heart Rhythm Society in 2020, the Heart Society Presidential Award in July of 2021, and received the Pioneer in Cardiac Electrophysiology Award and while presenting at the KCHRS national meeting in 8/2021.
Dr. Packer is active in the Heart Rhythm Society where he is a past president and was a member of the Board of Trustees. He is also active in the American Heart Association and the American College of Cardiology. He has served/currently serves on editorial boards for the Circulation Arrhythmia & Electrophysiology, American Heart Journal, the Journal of Cardiovascular Electrophysiology, Heart Rhythm journal, and the (EP) Journal of the American College of Cardiology. He also has served on multiple National Heart, Lung, and Blood Institute work groups on atrial fibrillation, ablation and planning for future NIH studies.
Dr. Packer has been an active teacher and mentor, and also lectures widely on cardiac arrhythmias. He has written or co-authored more than 412 journal publications and 631 abstracts. He has lectured extensively in national and international meetings, giving over 1,920 invited lectures in 41 countries. He has served on the executive committee of a number of NIH multicenter randomized clinical trials, Including the MUSTT, SCD-HeFT, and HAT Trials. Dr. Packer is also the International Principal Investigator of the recently reported NIH CABANA Trial. In this capacity he led the consortium of centers directing the trial. He is the PI of the Thermedical VT Needle Electrode study, and on the Executive Committee of the LESS VT Study.
Dr. Packer is a Mayo Clinician Investigator. His translational work focuses on the mechanisms and ablation of atrial fibrillation, ventricular tachycardia, and other cardiac arrhythmias, autologous fibroblast modulation of electrical impulse propagation in the heart, and the development of carbon particle catheter-free ablation of arrhythmias. His clinical work investigates 4/5 dimensional integrated image-guided ablation, and the development of new energy sources for the modification of cardiac tissue. His work has been funded in part by private foundations, the American Heart Association, and the NIH. A key part of his research is the development of the Catheter Free Particle Therapy Ablation Program. He is also the PI of the Extracorporeal Particle Therapy Ablation Using Proton and Carbon Beams, that is currently under way. Dr. Packer holds US and European patents in the development of intracardiac ultrasound and 4/5D imaging, and particle therapy ablation.
Dr. Packer is a member of the Arrhythmia & Electrophysiology Review editorial board.
Scientific Advisor
Research areas: Interventional Cardiology Education and Practice, Acute coronary syndromes, Hemodynamics, Hypertrophic Cardiomyopathy
Academic Distinctions
Honors:
2014 Master, Society of Cardiac Angiography and Intervention
2013 Elite Reviewer, Journal of American College of Cardiology
2012 Elite Reviewer, Cathand Cardiovascular Intervention
2011- ‘Best Doctors in America’, peer listing US News and World Report
2010 ‘Best Doctors in America’, peer listing US News and World Report
2010 ‘Best Cardiologists in Orange County’, peer listing, OC Register
2009 Simon Dack Award, Outstanding Scholarship from the JACC
2008 Southern California ‘Super’ Doctors (Cardiology), Orange Co Mag
1993-2005 Top Doctors in St. Louis (Cardiology), St. Louis Magazine
2004 Elite Reviewer, Journal of American College of Cardiology
1989 Certificate of Proficiency, SCAI
1976 Merck Scholarship Book Award
1975 Alpha Omega Alpha Medical Honor Society
Appointments
2014-Chief, Medicine Health Care Group, VA Long Beach Health Care System
2009-14 Chief, Division of Cardiology, VA Long Beach Health Care System2006- Associate Chief, Division of Cardiology, University California Irvine
2006- Professor of Medicine, Univ Calif Irvine, Orange, California
2008-2009 Director, Clinical Research, Long Beach Memorial Hospital 2005-2006 Director, Clinical Research, PCA, Costa Mesa, California
2005-2006 Voluntary Clinical Professor of Medicine, Cardiology, USC1991-2004 Professor of Medicine, St. Louis University School of Medicine1989-2004 Director, J.G. Mudd Cardiac Catheterization Lab, St. Louis Univ.1988-1991 Associate Professor of Medicine, SLU
1985-1993 Director Cardiac Cath lab, John Cochran VA , St. Louis
1985-1989 Associate Director, Cardiac Catheterization Laboratory, SLU
1985-1988 Assistant Professor of Medicine, Medicine/Cardiology, SLU
1984-1985 Associate Director, Cardiac Cath Lab. Audie L. Murphy VA UTSA
1982-1985 Assistant Professor of Medicine, Cardiology, Univ Texas HSC, San Antonio, Texas
1981-1982 Junior Associate, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Scientific Advisor
TRAINING AND FACULTY APPOINTMENTS
Faculty Appointment
Professor, Medicine
Mount Sinai-Icahn School of Medicine
Medical School
Grenada, 1987
Residency
Univ Conn Health Center
Internal Medicine, 1988 – 1991
Fellowship
Mt Sinai Hosp
Cardiovascular Disease, 1991 – 1994
Fellowship
Mt Sinai Hosp
Interventional Cardiology, 1994 – 1995
AWARDS AND CREDENTIALS
Board of trustees — SCAI
Program Committee for the American Heart Association Scientific Sessions
Board of directors — Harboring Hearts
Program Chair for Society of Cardiac Angiography and Interventions (SCAI- WIN (Women in Innovations)) Initiative
Chief Scientific Officer of the Clinical Trials Center at the Cardiovascular Research Foundation
Varinder Singh, MD, is responsible for the quality and delivery of cardiovascular care at Lenox Hill Hospital and Northwell Health’s Western Region. As chair, Dr. Singh has played an integral role in reestablishing Lenox Hill as a leading center for cardiovascular medicine in Manhattan.
Dr. Singh is secretary of the Lenox Hill Medical Board and a member of the hospital’s Credentials Committee and International Services Committee. He is an assistant professor of cardiology at the Zucker School of Medicine, and his professional memberships include the American College of Cardiology, Society of Cardiovascular Angiography and Interventions, Bronx Medical Society and New York Medical Society.
Eric A. Secemsky, MD
Scientific Advisor
Dr. Eric Secemsky is the Director of Vascular Intervention and an interventional cardiologist within the CardioVascular Institute at Beth Israel Deaconess Medical Center (BIDMC). He is also the Section Head of Interventional Cardiology and Vascular Research at the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology and an Assistant Professor of Medicine at Harvard Medical School. He received his medical degree from Northwestern University’s Feinberg School of Medicine as part of the combined BA/MD pathway and a Master’s of Science in Epidemiology from the Harvard School of Public Health. Dr. Secemsky completed his internal medicine training at the University of California, San Francisco (UCSF), and Cardiovascular Medicine, Interventional Cardiology, and Vascular Diagnostics and Intervention training all at Massachusetts General Hospital (MGH)/Harvard Medical School. Clinically, Dr. Secemsky splits his time attending in the cardiac catheterization lab and the inpatient and outpatient vascular medicine services. Dr. Secemsky is the primary vascular interventionalist within the BIDMC catheterization lab, where he does complex venous and arterial procedures, with a focus on peripheral artery disease.
Dr. Secemsky’s research involves utilizing real-world data to perform comparative effectiveness and outcomes research, with a focus on the treatment of peripheral vascular disorders. He has particular interests in drug delivery, intravascular imaging, antithrombotic therapy and pulmonary embolism intervention. Dr. Secemsky is also involved in clinical trial design and implementation and has served as an investigator on more than a dozen trials. Dr. Secemsky’s research program is funded by the National Institutes of Health (NIH), Harvard Medical School, extramural grants, and philanthropy. Dr. Secemsky has authored more than 100 publications and has mentored numerous medical students, residents, fellows, and junior faculty. He is an Associate Editor at Vascular Medicine and is on the Editorial Board at Circulation: Cardiovascular Interventions. He is also the current Chair of the PERT Consortium Research Committee, is a writing member of the 2022 ACC/AHA Guideline on the Management of Lower Extremity Peripheral Artery Disease (PAD) and is the co-director of the ACC’s Scientific Sessions’ Endovascular Program, SCAI’s Scientific Sessions’ Endovascular Program and SVM’s Fellows/APP Course.
William Fearon, MD graduated from Dartmouth College and received his medical degree from Columbia University College of Physicians and Surgeons, where he was elected into the Alpha Omega Alpha Medical Honor Society. He completed an Internal Medicine residency at Stanford University Medical Center serving an extra year as a Medical Chief Resident. He completed a General Cardiology and Interventional Cardiology fellowship at Stanford, spending his third year as the Chief Cardiology Fellow. He is currently a Professor of Medicine (Cardiology) and Director on Interventional Cardiology at Stanford University School of Medicine and the Chief of the Cardiology Section at the VA Palo Alto Health Care System. Dr. Fearon is board certified in cardiovascular medicine and interventional cardiology, and he is a fellow of the American College of Cardiology, the American Heart Association, and the Society of Cardiovascular Angiography and Interventions. He has been elected to the American Society for Clinical Investigation and the Association of University Cardiologists.
Scientific Advisor
Education & Training
University of Sheffield Medical School (UK)
Residency: University of Cambridge (UK)
Doctorate in Philosophy: University of Oxford (UK)
Post-doctoral Fellowship: Stanford University
Residency: Stanford University Medical Center
Fellowship: Stanford University Medical Center
Fellowship: Mount Sinai Medical Center
Honors and Awards
CRF/TCT – Best Coronary Case of TCT 2019
EuroPCR – “PCR’s got Talent” # 1 ranked scientific submission (1stof 1018)
Columbia University Louis V Gerstner Jr. Scholar
CRF/TCT Thomas J Linnemeier Spirit of Interventional Cardiology Runner-up
Best of Basic Science, American Heart Association
Northwestern Cardiovascular Young Investigator 3rd Place
Columbia University Paul Marks Scholar
American Heart Association Young Investigator
(Council on Functional Genomics and Translational Biology)
American Heart Association Peripheral Vascular Disease Award
(Council on Peripheral Vascular Disease)
Stanford Cardiovascular Medicine Outstanding Clinical Fellow Award
Stanford Cardiovascular Institute Gerald M Reaven Award (Basic Science)
Stanford Cardiovascular Institute Young Investigator Award (Basic Science)
American College of Cardiology Young Investigator Award
(Molecular and Cellular Cardiology)
British Atherosclerosis Society/British Society for Cardiovascular Research
Young Investigator Award (Basic Science)
British Cardiovascular Society Young Researcher Award (Clinical Science)
UK Vascular Society Sol Cohen (Founder’s) Young Investigator Award
William R Miller Senior Scholar– St Edmund Hall, University of Oxford
Christ Church College Senior Scholarship
Wellcome Trust Fellowship in Cardiovascular Medicine
University of Sheffield School of Medicine Valedictorian (Gold Medal)- Final MB ChB
Honors and Distinction Final MB ChB
Dr. Mark Gregory Baker (Ashby De La Zouch) Prize in Medicine and Surgery
Glaxo Wellcome Prize in Basic Clinical Sciences
Distinction Genito-urinary, Endocrine, Reproduction, Gastro-intestinal, Liver
Distinction Hematology, Immunology, Genetics, Oncology
University Overseas Scholarship for academic excellence
Ontario Scholar for academic excellence
Scientific Advisor
Scientific Advisor
Paul Teirstein, MD, is the chief of cardiology and director of interventional cardiology for Scripps Clinic and director of the Scripps Prebys Cardiovascular Institute for Scripps Health. He received training at the Mount Sinai School of Medicine, the Brigham and Women’s Hospital, Stanford University, the Mid-America Heart Institute, and the National Institutes of Health. Dr. Teirstein joined Scripps in 1987 and is the founder and director of the interventional cardiology program at Scripps Clinic. Through this program he is leading the way in training a new generation of interventional cardiologists.
With a primary focus on complex coronary interventions and new technology development, Dr. Teirstein has played an active role in the initial development and clinical investigation of coronary stent procedures, rotablator atherectomy, transluminal extraction atherectomy, coronary angioscopy and the utilization of cardiopulmonary support. Dr. Teirstein pioneered the first effective treatment for restenosis (low dose radiation therapy) and was one of the early investigators of medicated stents. Recent areas of investigation include new technology for minimally invasive transcatheter aortic valve replacement (PARTNER trial) and transcatheter treatment of hypertension (Simplicity trial).
The author of numerous publications, Dr. Teirstein has lectured throughout the world on state-of-the-art interventional cardiology techniques. He is an internationally recognized leader in cardiology and has received countless awards for both research and clinical excellence. Dr. Teirstein currently performs in excess of 800 stent procedures per year and maintains an active clinical research unit at Scripps Clinic, where he strives to offer patients the most advanced cardiovascular care available worldwide.
He is also a member of multiple professional societies including the American Heart Association, the Society of Cardiac Angiography and Interventions, and is a fellow of the American College of Cardiology.
Scientific Advisor
David R. Holmes, Jr., M.D., is the Scripps Professor in Cardiovascular Medicine at the Mayo Clinic in honor of Dr. George Gura, Mayo Clinic, Rochester, MN. He has been a member of the Department of Cardiovascular Medicine for 40 years, primarily involved in interventional cardiology, electrophysiology and pacing, patient care and cardiovascular education. Dr. Holmes is an interventional cardiologist and very much enjoys the practice of interventional cardiology taking care of patients with all types of cardiovascular diseases. He has been involved in multiple research studies both as a clinical investigator and as the principal investigator. He was the director of Electrophysiology and Pacing, Mayo Clinic and Mayo Foundation from 1981 to 1985 and then became the director of the Cardiac Catheterization Laboratory from 1984 to 2003.
His subspecialty interests include the development of strategies for stroke prevention in the setting of nonvalvular atrial fibrillation, treatment of pulmonary vein stenosis, valvular heart disease, hypertrophic cardiomyopathy, and acute and chronic coronary artery disease.
Bruce Samuels, MD
Scientific Advisor
Dr. Samuels is a clinical and interventional cardiologist specializing in the care of patients with a broad range of cardiac conditions. His office and hospital based practice involves the care of both chronic and acute cardiac conditions – including coronary disease, congestive heart failure, valvular heart disease and arrhythmias. In addition to his clinical practice in coronary intervention, Dr. Samuels has actively participated in numerous interventional trials including IVUS guided therapy, functional measurement and microvascular disease. He is also working closely with the Women’s Heart Center based at CSMC, working as the lead interventionalist of the active coronary reactivity research there.
As co-chair of a 30 day readmissions task force, he has helped to shape policy for CSMC in its efforts to improve quality delivery of care. He has frequently been invited as faculty to many scientific meetings and is a sought after speaker for numerous peer educational platforms
He has published extensively in peer reviewed journals in the fields of interventional cardiology, microvascular disease and angina. He continues to participate in a wide range of interventional and clinical cardiology trials.
After serving as chief resident in medicine at L.A.County Harbor-UCLA Medical Center, Dr. Samuels completed his fellowship in cardiology and interventional cardiology at Cedars-Sinai Medical Center. He has participated in a wide variety of interventional and non-interventional clinical trials.
He is married and is the proud father of three sons; his outside interests include contemporary art and long distance running.
Chair of Technology Advisory Board
Charles G. Sodini received the B.S.E.E. degree from Purdue University, and the M.S.E.E. and the Ph.D. degrees from the University of California, Berkeley.
Dr. Sodini began his career as a member of the technical staff at Hewlett-Packard Laboratories, where he worked on the design of Dynamic Random Access Memory (DRAM). He joined the faculty of the Massachusetts Institute of Technology, in 1983, where he is currently the LeBel Professor of Electrical Engineering. His research interests are focused on medical electronic systems for monitoring and imaging. These systems require state-of-the-art mixed signal integrated circuit and systems with extremely low energy dissipation. He is the co-founder of the Medical Electronic Device Realization Center at MIT.
Along with Prof. Roger T. Howe, he is a co-author of an undergraduate text on integrated circuits and devices entitled “Microelectronics: An Integrated Approach.” He also studied the Hong Kong/South China electronics industry in 1996-97 and has continued to study the globalization of the electronics industry.
Dr. Sodini was a co-founder of SMaL Camera Technologies a leader in imaging technology for consumer digital still cameras and machine vision cameras for automotive applications. He has served on a variety of IEEE Conference Committees, including the International Electron Device Meeting where he was the 1989 General Chairman. He has served on the IEEE Electron Device Society Administrative Committee, was president of the IEEE Solid-State Circuits Society from 2002-2004 and was the Chair of the Executive Committee for the VLSI Symposium from 2006-2014. He serves on a variety of industry boards and is a Fellow of the IEEE.
Technology Advisory Board
Keith
Fife received the Bachelor of Science and Master of Engineering degrees in
Electrical Engineering and Computer Science from MIT and a Ph.D in Electrical
Engineering from Stanford University as a Hertz Foundation Fellow researching
advanced imaging devices.
Keith co-founded SMaL Camera Technologies to develop image sensors and systems
for consumer and automotive imaging. He was the Chief Designer at Ion Torrent,
Life Technologies and Thermo Fisher developing high throughput DNA sequencing
chips. He was Chief Technology Officer for Butterfly Network delivering
Ultrasound on Chip technology to the market using MEMS-based transducer arrays
integrated with CMOS. He served as Chief Technology Officer for Quantum Si
developing the chips and manufacturing processes for protein sequencing. He has
served as a technical advisor to Cypress Semiconductor, 4Catalyzer and
Hyperfine and is a Founding Advisor for Chromatic, developing products in the
high-tech healthcare space. Keith has served on various academic programs
including the ISSCC technical program committee for IMMD.
Keith has several patents and publications in digital and analog IC design,
image sensors, cameras, DNA sequencing, Ultrasound imaging, and MRI. His
company won “Best of CES” in 2001 and the “World’s Thinnest Camera” from
Guinness World Records in 2002. The Butterfly IQ was listed as one of the 100
greatest innovations of 2018 by Popular Science and won several medical design
awards.
Technology Advisory Board
Mr. Bidermann brings more than a quarter-century of engineering experience to bear on the management and technical issues confronting start-up and established companies in the computer industry. His career has been marked by successful engagements at some of the biggest names in the technology arena, as well as stints with aggressive young firms poised to deliver new innovations to the marketplace. Mr. Bidermann specializes in semiconductors, embedded systems and ASIC and many other areas. Mr. Bidermann is currently the President of BK Associates. Past positions include VP of Engineering for Airgain, Inc., Sr. VP for Zeebo, Inc., Executive VP of Nuelight Corp, VP of Engineering and Sensor Development for Pixim, Inc. among others. Mr. Bidermann received his BS, MS, EE/CS from Massachusetts Institute of Technology.
